pioglitazone has been researched along with Cancer of Pancreas in 8 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among 193,099 persons in the bladder cancer cohort, 34,181 (18%) received pioglitazone (median duration, 2." | 7.81 | Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. ( Bilker, W; Ehrlich, SF; Ferrara, A; Habel, LA; Hedderson, MM; Lewis, JD; Mamtani, R; Nessel, L; Peng, T; Quesenberry, CP; Strom, BL; Van Den Eeden, SK; Vaughn, DJ, 2015) |
| "Among 193,099 persons in the bladder cancer cohort, 34,181 (18%) received pioglitazone (median duration, 2." | 3.81 | Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. ( Bilker, W; Ehrlich, SF; Ferrara, A; Habel, LA; Hedderson, MM; Lewis, JD; Mamtani, R; Nessel, L; Peng, T; Quesenberry, CP; Strom, BL; Van Den Eeden, SK; Vaughn, DJ, 2015) |
| " The authors analysed the effects of two TZD, rosiglitazone and pioglitazone, on invasiveness of human pancreatic carcinoma cell lines in order to evaluate the potential therapeutic use of these drugs in pancreatic adenocarcinoma." | 3.72 | Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms. ( Casini, A; Ceni, E; Crabb, DW; Galli, A; Grappone, C; Mello, T; Milani, S; Salzano, R; Surrenti, C; Surrenti, E, 2004) |
| "Although a correlation between pancreatic cancer and diabetes mellitus has long been suspected, the potential role diabetes mellitus plays in the pathogenicity of both hepatocellular carcinoma and colon cancer is becoming increasingly well defined." | 2.50 | Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. ( Herrigel, DJ; Moss, RA, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stern, JH | 1 |
| Arriaga, Y | 1 |
| Gupta, A | 1 |
| Verma, U | 1 |
| Karri, S | 1 |
| Syed, S | 1 |
| Khosama, L | 1 |
| Mansour, J | 1 |
| Meyer, J | 1 |
| Scherer, PE | 1 |
| Beg, MS | 1 |
| Herrigel, DJ | 1 |
| Moss, RA | 1 |
| Lewis, JD | 1 |
| Habel, LA | 1 |
| Quesenberry, CP | 1 |
| Strom, BL | 1 |
| Peng, T | 1 |
| Hedderson, MM | 1 |
| Ehrlich, SF | 1 |
| Mamtani, R | 1 |
| Bilker, W | 1 |
| Vaughn, DJ | 1 |
| Nessel, L | 1 |
| Van Den Eeden, SK | 1 |
| Ferrara, A | 1 |
| Elmaci, İ | 1 |
| Altinoz, MA | 1 |
| Koga, H | 1 |
| Selvendiran, K | 1 |
| Sivakumar, R | 1 |
| Yoshida, T | 1 |
| Torimura, T | 1 |
| Ueno, T | 1 |
| Sata, M | 1 |
| Bunt, SK | 1 |
| Mohr, AM | 1 |
| Bailey, JM | 1 |
| Grandgenett, PM | 1 |
| Hollingsworth, MA | 1 |
| Galli, A | 1 |
| Ceni, E | 1 |
| Crabb, DW | 1 |
| Mello, T | 1 |
| Salzano, R | 1 |
| Grappone, C | 1 |
| Milani, S | 1 |
| Surrenti, E | 1 |
| Surrenti, C | 1 |
| Casini, A | 1 |
| Takeuchi, Y | 1 |
| Takahashi, M | 1 |
| Sakano, K | 1 |
| Mutoh, M | 1 |
| Niho, N | 1 |
| Yamamoto, M | 1 |
| Sato, H | 1 |
| Sugimura, T | 1 |
| Wakabayashi, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cohort Study of Pioglitazone and Bladder Cancer in Patients With Diabetes[NCT01637935] | 193,099 participants (Actual) | Observational | 2004-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Incident bladder cancers were identified from January 1, 1997 to December 31, 2012. (NCT01637935)
Timeframe: January 1, 1997 to December 31, 2012
| Intervention | events per 100,000 person years (Number) |
|---|---|
| Pioglitazone Exposed Group | 89.8 |
| Pioglitazone Unexposed Group | 75.9 |
(NCT01637935)
Timeframe: January 1, 1997 to December 31, 2012
| Intervention | events per 100,000 person years (Number) | ||
|---|---|---|---|
| 1 - 14000 mg | 14001 - 40000 mg | >40000 mg | |
| Pioglitazone Exposed Group | 69.1 | 96.9 | 101.4 |
| Pioglitazone Unexposed Group | NA | NA | NA |
(NCT01637935)
Timeframe: January 1, 1997 to December 31, 2012
| Intervention | events per 100,000 person years (Number) | ||
|---|---|---|---|
| Less than 1.5 years | 1.5 - 4.0 years | More than 4 years | |
| Pioglitazone Exposed Group | 67.5 | 88.4 | 113.7 |
| Pioglitazone Unexposed Group | NA | NA | NA |
(NCT01637935)
Timeframe: January 1, 1997 to December 31, 2012
| Intervention | events per 100,000 person years (Number) | ||
|---|---|---|---|
| Less than 4.5 years | 4.5 -8.5 years | More than 8.0 years | |
| Pioglitazone Exposed Group | 68.2 | 111.6 | 125.8 |
| Pioglitazone Unexposed Group | NA | NA | NA |
(NCT01637935)
Timeframe: January 1, 1997 to December 31, 2012
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| PUNLMP | In situ | Local | Regional | Distant | Undetermined | |
| Pioglitazone Exposed Group | 1 | 50 | 40 | 4 | 2 | 3 |
| Pioglitazone Unexposed Group | 1 | 49 | 38 | 6 | 3 | 3 |
2 reviews available for pioglitazone and Cancer of Pancreas
| Article | Year |
|---|---|
Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Complications; Humans; Hyp | 2014 |
A Metabolic Inhibitory Cocktail for Grave Cancers: Metformin, Pioglitazone and Lithium Combination in Treatment of Pancreatic Cancer and Glioblastoma Multiforme.
Topics: Brain Neoplasms; Cell Proliferation; Drug Therapy, Combination; Gene Expression Regulation, Neoplast | 2016 |
6 other studies available for pioglitazone and Cancer of Pancreas
| Article | Year |
|---|---|
Fasting and Glucose-Stimulated Changes in Plasma Glucagon in Pancreatic Cancer: Potential Biomarkers for Detection?
Topics: Aged; Biomarkers; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucose; Glucose Tolerance T | 2019 |
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.
Topics: Adult; Aged, 80 and over; Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type 2; Female; H | 2015 |
PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; | 2012 |
Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma | 2013 |
Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cell Division; DNA, Neoplasm; Dose-Response Rela | 2004 |
Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma.
Topics: Animals; Antineoplastic Agents; Carcinogens; Cricetinae; Female; Hyperlipidemias; Ligands; Lipoprote | 2007 |